Monoclonal antibodies directed against hepatitis B viruses
US7785586B2 · kind B2 · utility
2Cited by
4References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 2001 |
| Grant date | Aug 31, 2010 |
| Priority date | — |
| Expiry date | Mar 27, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a monoclonal antibody capable of binding to a wild-type HBsAg antigen and to at least one, preferably at least two and advantageously more than two, mutant forms of the HBsAg antigen, said monoclonal antibody binding to a peptide sequence consisting of at least 6 contiguous amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding to the peptide sequence constituted by the 199-208 region of the HBsAg antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.